此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

干扰素 γ 作为重症监护病房攻击性免疫抑制后治疗的效果,随机贝叶斯双盲对照试验与安慰剂对比 (INFINITY)

2026年11月10日 更新者:Assistance Publique - Hôpitaux de Paris

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

研究概览

详细说明

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

This immunological adaptation, initially implemented as a host defense mechanism to protect against an overwhelming systemic reaction, can, if prolonged, lead to multiple complications resulting in significant delayed morbidity and mortality. Diagnosis is based on the use of immuno-inflammatory biomarkers, the most widely studied of which is monocyte expression of major histocompatibility complex type II molecules (mHLA-DR).

We have recently confirmed that PAIS can affect all types of patients admitted to the intensive care unit, but mainly occurs in the most severe patients. We also showed that the occurrence of PAIS was strongly associated with the subsequent occurrence of secondary infection and excess mortality.

Currently, there is no treatment with proven efficacy for PAIS, but several drugs have been shown to restore leukocyte function in-vitro. Several teams have reported the use of immunostimulatory molecules in patients with treatment failure, with a good safety profile and encouraging results. We believe that earlier treatment of patients with proven PAIS could improve their clinical outcome.

研究类型

介入性

注册 (估计的)

170

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Limoges、法国、87000
      • Nancy、法国
        • 招聘中
        • Pr Antoine Kimmoun
        • 接触:
      • Paris、法国
        • 招聘中
        • Pr Dépret
        • 接触:
      • Paris、法国、75010
        • 招聘中
        • Pr Benjamin Chousterman
        • 接触:
      • Paris、法国、75013
      • Paris、法国
        • 招聘中
        • Pr Megarbane
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patient ≥ 18 years old
  • SOFA score for first 24 hours post-admission ≥ 6
  • Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
  • mHLA-DR< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
  • Patient affiliated to a social security scheme
  • Written informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible

Exclusion Criteria:

  • Patient with estimated life expectancy of less than 3 months
  • Patients with a predicted remaining stay in intensive care < 72 hours
  • Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score < 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
  • Pregnant or breast-feeding women
  • Contraindication of Imukin (hypersensitivity to interferon gamma-1b or known hypersensitivity to related products, such as another interferon)
  • Patients on immunosuppressive therapy, including long-term corticosteroid therapy (>2.5mg/d prednisone equivalent)
  • Patients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
  • Patient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
  • People under court protection and protected adults

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:interferon gamma-1b injection

Patients randomized to the experimental arm will receive :

Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

安慰剂比较:Placebo injection

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
number of days alive without mechanical ventilation
大体时间:on Day 28 after drug administration

number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day

on Day 28 after drug administration

次要结果测量

结果测量
措施说明
大体时间
Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo
大体时间:Day 1 to Day 7 and at Day 28 post randomization

Evolution of mHLA-DR measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo.

Day 1 to Day 7 and at Day 28 post randomization
Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo
大体时间:Day 0, Day 3 and at Day 7 post randomization

Evolution of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at Day 0, Day 3 and Day 7, or at discharge from intensive care if it occurs before (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo

Day 0, Day 3 and at Day 7 post randomization
mortality at Day 28 and Day 90 after randomization
大体时间:Day 28 and Day 90 after randomization

Mortality rate at Day 28 and Day 90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo

Day 28 and Day 90 after randomization
incidence of nosocomial infections during intensive care unit stay
大体时间:from Day 0 to Day 28 (or the discharge from intensive care)

The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo

from Day 0 to Day 28 (or the discharge from intensive care)
number of days alive whithout antibiotic
大体时间:Day 28 after drug administration

Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo

Day 28 after drug administration
length of stay in intensive care between patients
大体时间:from Day 0 to Day 28 (or the discharge from intensive care)

Number of days in intensive care between patients treated with recombinant interferon gamma 1-b versus placebo

from Day 0 to Day 28 (or the discharge from intensive care)
- Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo
大体时间:From inclusion to Day 7

Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo

From inclusion to Day 7
Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo
大体时间:Day 0, Day 3 and Day 7 after randomization

Evolution of the transcriptomic profile of circulating peripheral blood mononuclear cells (PBMCs) using scRNAseq analysis measured at Day 0, Day 3 and Day 7 or upon discharge from intensive care if this occurs earlier.

Day 0, Day 3 and Day 7 after randomization
Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo
大体时间:Day 0 to Day 7 and at Day 28 post randomization

Evolution and kenetics of the leucocyte count measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo

Day 0 to Day 7 and at Day 28 post randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Benjamin Chousterman, Professor、APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月24日

初级完成 (估计的)

2029年3月1日

研究完成 (估计的)

2029年5月1日

研究注册日期

首次提交

2024年11月12日

首先提交符合 QC 标准的

2024年11月15日

首次发布 (实际的)

2024年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅